NASDAQ:CDXC
ChromaDex Corporation Stock News
$3.44
+0.0500 (+1.47%)
At Close: Apr 26, 2024
First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)
10:33am, Wednesday, 03'rd Jun 2020
ChromaDex Corp. (NASDAQ: CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a study evaluating
First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)
12:00am, Wednesday, 03'rd Jun 2020
ChromaDex Corp. (NASDAQ: CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, ann
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
10:32am, Monday, 01'st Jun 2020
ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled "Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
12:00am, Monday, 01'st Jun 2020
ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide (NAD+) in Human Health
Here is What Hedge Funds Think About ChromaDex Corporation (CDXC)
07:15pm, Wednesday, 27'th May 2020
In this article we will take a look at whether hedge funds think ChromaDex Corporation (NASDAQ:CDXC) is a good investment right now. We check hedge fund and billionaire investor sentiment before delvi
ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled "What New Dietary Ingredient Master Files Mean for Innovation & Compliance," hosted by the American Confere
ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled “What New Dietary Ingredient Master Files Mean for Innova
ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020
Edited Transcript of CDXC earnings conference call or presentation 11-May-20 8:30pm GMT
07:20pm, Tuesday, 12'th May 2020
Q1 2020 Chromadex Corp Earnings Call
8-K: ChromaDex Corp.
05:50am, Tuesday, 12'th May 2020
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE...
ChromaDex Corporation (CDXC) Q1 2020 Earnings Call Transcript
05:01am, Tuesday, 12'th May 2020
Ladies and gentlemen, thank you for standing by and welcome to ChromaDex Corporation's First Quarter 2020 Earnings Conference Call. This afternoon, ChromaDex issued a news release announcing the comp
ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2020 Results - Earnings Call Transcript
01:40am, Tuesday, 12'th May 2020
ChromaDex Corporation (NASDAQ:CDXC) Q1 2020 Results Earnings Conference Call May 11, 2020, 04:30 PM ET Company Participants Brianna Gerber - VP, FP&A and IR
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Monday, 11'th May 2020
ChromaDex (CDXC) delivered earnings and revenue surprises of 18.18% and 4.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Corporation Reports First Quarter 2020 Financial Results
08:01pm, Monday, 11'th May 2020
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2020 financial results.
ChromaDex Corporation Reports First Quarter 2020 Financial Results
12:00am, Monday, 11'th May 2020
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2020 financial results. “We had a strong first quarter with total net sales of $14.3 millio
